TEVA PHARMACEUTICAL-SP ADR

Teva’s new data on Austedo shows real‑world benefits for Huntington’s patients, boosting quality‑of‑life and caregiver ease—insights that could reshape pricing, reimbursement and profitability.

Teva launches AHZANTIVE, a cost‑effective aflibercept biosimilar, targeting 15% EU market share and $1.5 bn sales—showing how strategic partnerships accelerate biosimilar growth.